Final results of 2-dose fractionation of 177mLu-J591 for progressive metastatic castration-resistant prostate cancer mCRPC).

被引：8
|
作者：
Tagawa, Scott T.
Batra, Jaspreet
Vallabhajosula, Shankar
Jhanwar, Yuliya
Christos, Paul J.
Emmerich, Lauren
Karir, Beerinder S.
Karpenko, Irene
Lam, Linda
Febles, Victor R. A.
Molina, Ana M.
Beltran, Himisha
Goldsmith, Stanley J.
Bander, Neil Harrison
Nanus, David M.
机构：
[1] Weill Cornell Med, New York, NY USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Weill Cornell Med, New York Presbyterian Hosp, New York, NY USA
[4] New York Presbyterian Hosp Cornell, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5022
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Fractionated dose radiolabeled anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC).
    Batra, Jaspreet S.
    Karir, Beerinder S.
    Pinto-Chengot, Kavya
    Jhanwar, Yuliya
    Vallabhajosula, Shankar
    Christos, Paul J.
    Hodes, Gillian
    Lam, Linda
    Molina, Ana M.
    Beltran, Himisha
    Nanus, David M.
    Goldsmith, Stanley J.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [2] Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Osborne, Joseph
    Niaz, Muhammad Junaid
    Vallabhajosula, Shankar
    Vlachostergios, Panagiotis J.
    Thomas, Charlene
    Molina, Ana M.
    Sternberg, Cora N.
    Singh, Sharon
    Fernandez, Escarleth
    Babich, John
    Nanus, David M.
    Ballman, Karla V.
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [3] Final results of phase I/II trial of fractionated dose 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC)
    Tagawa, S. T.
    Sun, M.
    Sartor, O.
    Thomas, C.
    Molina, A. M.
    Sternberg, C. N.
    Nanus, D. M.
    Osborne, J.
    Bander, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S645 - S645
  • [4] Pilot study of "hyperfractionated" anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana M.
    Batra, Jaspreet S.
    Karir, Beerinder S.
    Jhanwar, Yuliya
    Vallabhajosula, Shankar
    Christos, Paul J.
    Lam, Linda
    Epstein, Jennifer
    Karpenko, Irene
    Beltran, Himisha
    Nanus, David M.
    Goldsmith, Stanley J.
    Bander, Neil H.
    Tagawa, Scott T.
    CANCER RESEARCH, 2016, 76
  • [5] A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).
    Sun, Michael
    Nauseef, Jones T.
    Lebenthal, Justin M.
    Niaz, Muhammad Junaid
    Singh, Sharon
    Chamberlain, Tessa A.
    Bissassar, Mahelia
    Patel, Amie
    Tan, Angela
    Vallabhajosula, Shankar
    Babich, John
    Christos, Paul J.
    Osborne, Joseph
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [6] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Bilusic, Marijo
    Karzai, Fatima
    Cordes, Lisa M.
    Strauss, Julius
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Niaz, Muhammad Junaid
    Osborne, Joseph
    Vallabhajosula, Shankar
    Beltran, Himisha
    Harshman, Lauren Christine
    Nanus, David M.
    Molina, Ana M.
    Faltas, Bishoy Morris
    Hackett, Amy
    Gracey, Lauren
    Sreekumar, Jyothi
    Babich, John
    Ballman, Karla V.
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [8] Fractionated dose radiolabeled antiprostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) with or without docetaxel for metastatic castration-resistant prostate cancer (mCRPC)
    Batra, Jaspreet S.
    Karir, Beerinder S.
    Vallabheiesula, Shenker
    Christos, Paul J.
    Hodes, Gillian
    Date, Pravin R.
    Nikolopoulou, Anastasia
    Jhanwar, Yuliya
    Beltran, Himisha
    Nanus, David M.
    Goldsmith, Stanley J.
    Bander, Nell Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [9] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Karzai, Fatima
    Cordes, Lisa M.
    Schlom, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [10] Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Sun, Michael
    Sartor, A. Oliver
    Thomas, Charlene
    Singh, Sharon
    Bissassar, Mahelia
    Fernandez, Escarleth
    Niaz, Muhammad Junaid
    Ho, Benedict
    Vallabhajosula, Shankar
    Babich, John
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Osborne, Joseph
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345